Lung Cancer Research Review, Issue 35

In this issue:

Association of toxic effects with shared antigens in NSCLC
Nivolumab for unresectable or recurrent thymic carcinoma
Erlotinib ± bevacizumab in EGFR+ NSCLC
Depth of response and outcomes in NSCLC
SABR for inoperable peripherally located stage 1 NSCLC
Alectinib in the first-line treatment of ALK +, advanced NSCLC
SBRT for centrally located NSCLC

Please login below to download this issue (PDF)